330 related articles for article (PubMed ID: 28869437)
21. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Gao YT; Chen XB; Liu HL
Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
[TBL] [Abstract][Full Text] [Related]
22. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
23. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
[TBL] [Abstract][Full Text] [Related]
25. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
26. Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort.
Nakagawa Y; Sasaki H; Ohara K; Ezaki T; Toda M; Ohira T; Kawase T; Yoshida K
World Neurosurg; 2017 Oct; 106():165-173. PubMed ID: 28666913
[TBL] [Abstract][Full Text] [Related]
27. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
28. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
[TBL] [Abstract][Full Text] [Related]
29. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
30. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
31. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
Wang W; Zhang L; Wang Z; Yang F; Wang H; Liang T; Wu F; Lan Q; Wang J; Zhao J
Oncotarget; 2016 Oct; 7(43):69991-69999. PubMed ID: 27588397
[TBL] [Abstract][Full Text] [Related]
32. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
[TBL] [Abstract][Full Text] [Related]
33. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
34. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
Chen H; Li X; Li W; Zheng H
J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
36. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
[TBL] [Abstract][Full Text] [Related]
38. MiRNA expression patterns predict survival in glioblastoma.
Niyazi M; Zehentmayr F; Niemöller OM; Eigenbrod S; Kretzschmar H; Schulze-Osthoff K; Tonn JC; Atkinson M; Mörtl S; Belka C
Radiat Oncol; 2011 Nov; 6():153. PubMed ID: 22074483
[TBL] [Abstract][Full Text] [Related]
39. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
40. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
